Menu
MorphoSys US

Investor & Media information

You are here

  1. Home
  2. Media and investors
  3. Investor & Media information

MorphoSys is strictly committed to the principle of fair disclosure. One of the most important foundations of our corporate communication is to inform all stakeholders simultaneously and comprehensively about the situation of the Company. We pay great attention to transparent and timely communication.

Corporate media releases

Date
Title

2021

  1. 02/03/2021
    MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease
  2. 01/03/2021
    Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance
    No download available
  3. 25/01/2021
    MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
  4. 12/01/2021
    MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
  5. 11/01/2021
    MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
  6. 06/01/2021
    MorphoSys Appoints Sung Lee as Chief Financial Officer
  7. 05/01/2021
    MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

2020

  1. 17/12/2020
    MorphoSys AG: Corporate Calendar 2021
  2. 07/12/2020
    Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
  3. 02/12/2020
    MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)

Pages

Order form for publications and reports

Ad-hoc releases

Date
Title

2021

  1. 01/03/2021
    Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance
    No download available

2020

  1. 27/10/2020
    Ad hoc: MorphoSys AG Raises its Financial Guidance for the Full Year 2020
  2. 13/10/2020
    Ad hoc: MorphoSys AG Launches an Offering of approx. EUR 325 Million Convertible Bonds
  3. 01/08/2020
    MorphoSys AG: Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
  4. 13/01/2020
    MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
    No download available

2019

  1. 18/11/2019
    Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
    No download available
  2. 29/10/2019
    MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
    No download available
  3. 28/10/2019
    MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
    No download available
  4. 03/07/2019
    Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
    No download available
  5. 24/06/2019
    Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
    No download available

Pages

Conferences

Friday, February 26, 2021
Webcast: 10th Annual SVB Leerink Global Healthcare Conference

Dr. Jean-Paul Kress presents the Company at the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021, 02:20pm EST (08:20pm CET).

Go to Webcast...

Archive

Date
Title
MP3

2021

  1. 02/26/2021

    Webcast: 10th Annual SVB Leerink Global Healthcare Conference

  2. 02/11/2021

    Guggenheim Healthcare Talks, 2021 Oncology Day

  3. 01/13/2021

    Webcast: 39th Annual J.P. Morgan Healthcare Conference

2020

  1. 12/16/2020

    Webcast: JMP Securities Hematology Summit

  2. 11/17/2020

    Stifel 2020 Virtual HC Conference

  3. 11/12/2020

    Conference Call and Webcast: Q3/9M 2020 Financial Results

  4. 09/29/2020

    Conference Call and Webcast: MorphoSys & Incyte Tafasitamab Expert Event

  5. 08/06/2020

    Conference Call and Webcast: Q2/H1 2020 Financial Results

  6. 08/03/2020

    Joint MorphoSys and Incyte Conference Call

  7. 06/18/2020

    Webcast: JMP Securities Hematology and Oncology Forum

  8. 06/10/2020

    Webcast: Goldman Sachs 41st Annual Global Healthcare Conference

  9. 06/03/2020

    Webcast: Jefferies 2020 Healthcare Conference

  10. 05/07/2020

    Conference Call and Webcast: Q1 2020 Financial Results

  11. 03/19/2020

    Conference Call and Webcast: Year End 2019

Pages

Company Update

Date
Venue
Download

2020

  1. 01/13/2021
    Company Update

Pictures

Technology

Ylanthia

Ylanthia technology

Slonomics

Slonomics technology

HuCAL

HuCAL antibody library

HuCAL

Scientist working with the HuCAL library

Lab shots

Antibody purification

Scientist in protein chemistry lab

Daily work

MorphoSys scientist working in laboratory

Scientist with petri dishes

MorphoSys scientist handling petri dishes

Cell culture experiment

MorphoSys scientist in cell culture lab

Miscellaneous

MorphoSys Building Planegg

View of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Building Planegg

Entrance of the Building of MorphoSys in Planegg/Munich, Germany

MorphoSys Logo
MorphoSys Footage Video

Copyright notice: The photos provided for download on this website can be used free of charge in the context of editorial reporting with the indication of the photo credit "©MorphoSys AG".

 

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the Monjuvi(®) US website which is intended for US residents.

Do you wish to proceed?

Yes No